

Mixed 1Q; strong growth in 2H led by defense order ramp up

Auto & Auto Ancillaries ▶ Result Update ▶ August 10, 2026

CMP (Rs): 2,093 | TP (Rs): 2,400

BHFC logged a mixed 1Q, with consolidated revenue growth accelerating to 19% yoy (vs 18% in 4QFY26) and EBITDA up 5% yoy. Consolidated EBITDAM fell 190bps qoq to 15.3% (estimate: 15.6%), amid 240bps qoq decline in standalone operations (160bps hit from commodity/energy/logistics costs) and 170bps qoq decline in subsidiary operations (EBITDA loss in the US due to a breakdown). Demand outlook for BHFC remains robust, with a pronounced 2H and margin recovery from 2Q, driven by 1) sustained growth in India CVs; 2) healthy momentum in India PVs; 3) strong ramp-up in the defense business, led by order execution (ATAGS/QCB Carbine production from 2H; scale-up over 3Y); 4) sustained demand recovery in North American CVs (aging fleet and production rebound); and 5) healthy growth in other industrial verticals (expects 2x revenue in Aerospace). Owing to these positives, BHFC expects 20-25% revenue growth in FY27 for its India manufacturing operations, as it continues to re-evaluate the global footprint given profitability-related challenges in the medium term (part of EU steel production to be transferred to India post-restructuring). We revise FY27E/28E EPS by 4-5% and raise our TP by 14% to Rs2,400 (from Rs2,100 earlier) at 23x Jun-28E EV/EBITDA.

Miss on revenue; higher commodity/energy/logistics costs hit margins

Consolidated revenue rose ~19% yoy. SA revenue was up ~12% yoy. Domestic Auto revenue growth was 3.5% yoy, led by 2%/7% growth in PVs/CVs. Domestic non-auto revenue rose 16% yoy. Exports' recovery continued, with 12% yoy growth vs -12%/-21% in 4Q/3QFY26. Consolidated EBITDA rose 5% yoy; EBITDAM was down 190bps qoq on higher staff costs/other expenses. Subsidiary revenue (C-S) was up 27% yoy, with EBITDAM at 5.4% vs 7.1%/8.1% in 4Q/3QFY26. Consolidated PAT was down 5% yoy.

Earnings call KTAs

1) BHFC expects FY27 to be a strong year (2H more robust), with FY28 also strong, driven by growth capex and new businesses. 2) It plans organic capex of ~Rs18bn in India for FY27 (a fundraise of up to Rs25bn is planned for growth capex in large engines, power generation, semiconductor components, aerospace, and an energetics plant in AP). 3) BHFC secured new orders of Rs13.5bn in 1Q, including Rs6.8bn for Defense (order book: Rs112bn vs Rs110bn as of Mar-26). 4) The defense business targets a steady-state annual margin of 22-23%, while aerospace is expected to double its current Rs4bn revenue in 2Y. 5) The Odisha mega-site project (large aerospace components, multimodal facilities) faces delays on time-consuming local, central, and forest environmental clearances. 6) 1QFY27 faced manpower challenges, from the Iran war and LPG crisis, which sent contract/migrant labor home, impacting sub-suppliers and steel companies. Manpower is at 70-75% of normalcy, with some yet to return. 7) The restructuring of Bharat Forge CDP (steel business, Germany) includes a non-cash Rs30mn manpower-redundancy impact, with the entity ceasing to exist by end-CY27; part of operations to shift to India. 8) The India/NA outlook is very strong, Europe CV is strong, and PV neither strong nor weak. 9) Consumer demand for infrastructure-based assets in India is rising sharply, however, US tariffs on raw aluminum (50% from Canada) pose a challenge to achieving targeted margins.

Target Price – 12M	Jun-27
Change in TP (%)	14.3
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	14.7


Stock Data	BHFC IN
52-week High (Rs)	2,295
52-week Low (Rs)	1,101
Shares outstanding (mn)	478.1
Market-cap (Rs bn)	1,001
Market-cap (USD mn)	10,501
Net-debt, FY27E (Rs mn)	41,660.3
ADTV-3M (mn shares)	1.5
ADTV-3M (Rs mn)	2,620.7
ADTV-3M (USD mn)	27.5
Free float (%)	54.7
Nifty-50	24,583.8
INR/USD	95.3

Shareholding, Jun-26

Promoters (%)	44.1
FPIs/MFs (%)	15.1/32.3

Price Performance

(%)	1M	3M	12M
Absolute	(1.1)	5.2	84.4
Rel. to Nifty	(2.6)	3.5	82.7

1-Year share price trend (Rs)**Bharat Forge: Financial Snapshot (Consolidated)**

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	151,228	168,117	206,548	247,043	293,147
EBITDA	26,939	29,267	38,621	47,676	57,453
Adj. PAT	10,982	12,341	16,543	22,750	28,681
Adj. EPS (Rs)	23.0	25.8	34.6	47.6	60.0
EBITDA margin (%)	17.8	17.4	18.7	19.3	19.6
EBITDA growth (%)	5.3	8.6	32.0	23.4	20.5
Adj. EPS growth (%)	11.0	12.4	34.1	37.5	26.1
RoE (%)	13.4	13.1	16.3	19.6	21.1
RoIC (%)	11.8	11.9	13.9	17.4	20.1
P/E (x)	106.3	92.7	60.5	44.0	34.9
EV/EBITDA (x)	38.5	35.8	27.0	21.7	17.9
P/B (x)	10.8	10.4	9.3	8.0	6.8
FCFF yield (%)	0.3	0.1	1.5	1.7	1.6

Source: Company, Emkay Research

Chirag Jainchirag.jain@emkayglobal.com
+91-22-66242428**Nandan Pradhan**nandan.pradhan@emkayglobal.com
+91-22-66121238**Marazbaan Dastur**marazbaan.dastur@emkayglobal.com
+91-22-66121281**Sanskar Sahuji**sanskar.sahuji@emkayglobal.com
+91 22 66121245

Exhibit 1: Consolidated financials – Revenue up ~19% yoy, with EBITDA up 5% yoy; EBITDAM was down by 190bps qoq

Consolidated (Rs mn)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	yoy (%)	qoq (%)
Revenue	41,061	36,885	34,755	38,526	39,087	40,319	43,429	45,280	46,399	18.7	2.5
Growth yoy (%)	6	-2	-10	-7	-5	9	25	18	19		
Expenditure	33,652	30,412	28,512	31,713	32,358	33,063	35,930	37,498	39,305	21.5	4.8
as a % of sales	82.0	82.5	82.0	82.3	82.8	82.0	82.7	82.8	84.7		
Consumption of RM	18,369	15,643	14,698	17,234	16,962	17,674	19,742	21,518	20,685	22.0	(3.9)
as a % of sales	44.7	42.4	42.3	44.7	43.4	43.8	45.5	47.5	44.6		
Employee cost	4,987	4,672	4,362	4,678	5,137	5,206	5,346	5,346	5,935	15.5	11.0
as a % of sales	12.1	12.7	12.5	12.1	13.1	12.9	12.3	11.8	12.8		
Other expenditure	10,296	10,097	9,452	9,801	10,260	10,183	10,843	10,635	12,684	23.6	19.3
as a % of sales	25.1	27.4	27.2	25.4	26.2	25.3	25.0	23.5	27.3		
EBITDA	7,410	6,473	6,244	6,813	6,729	7,257	7,499	7,782	7,095	5.4	(8.8)
Growth yoy (%)	24	4	-11	6	-9	12	20	14	5		
EBITDA margin (%)	18.0	17.5	18.0	17.7	17.2	18.0	17.3	17.2	15.3		
Depreciation	2,183	2,133	2,182	2,238	2,261	2,409	2,488	2,551	2,633	16.4	3.2
EBIT	5,227	4,339	4,061	4,576	4,468	4,848	5,011	5,231	4,462	(0.1)	(14.7)
Other income	516	616	384	621	497	535	425	530	572	15.1	8.1
Interest	1,237	1,098	960	880	822	801	766	844	897	9.1	6.3
PBT	4,506	3,858	3,485	4,317	4,143	4,582	4,669	4,917	4,137	(0.1)	(15.9)
Total tax	1,250	1,419	1,342	1,415	1,271	1,576	1,344	1,587	1,343	5.7	(15.3)
Minority interest/Associate share	-289	3	15	29	35	14	126	17	111	216.4	551.1
Adjusted PAT	3,546	2,436	2,128	2,873	2,837	2,992	3,199	3,313	2,683	(5.4)	(19.0)
Growth yoy (%)	59	6	-20	17	-20	23	50	15	-5		
Extraordinary items loss/(gain)	-1,518	0	0	-53	0	0	-557	-987	-3,580		
Reported PAT	2,028	2,436	2,128	2,820	2,837	2,992	2,642	2,326	-897	(131.6)	(138.6)

(%)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	yoy (bps)	qoq (bps)
EBITDAM	18.0	17.5	18.0	17.7	17.2	18.0	17.3	17.2	15.3	(193)	(190)
EBITM	12.7	11.8	11.7	11.9	11.4	12.0	11.5	11.6	9.6	(181)	(194)
EBTM	11.0	10.5	10.0	11.2	10.6	11.4	10.8	10.9	8.9	(168)	(194)
PATM	8.6	6.6	6.1	7.5	7.3	7.4	7.4	7.3	5.8	(148)	(153)
Effective tax rate	27.7	36.8	38.5	32.8	30.7	34.4	28.8	32.3	32.5	179	20

Source: Company, Emkay Research

Exhibit 2: Actual vs Estimates

Consolidated (Rs mn)	Actuals	Emkay estimates	% variance	Consensus	% variance
Net sales	46,399	48,859	(5.0)	46,593	(0.4)
EBITDA	7,095	7,622	(6.9)	8,099	(12.4)
EBITDA margin (%)	15.3	15.6	-31 bps	17.4	-209 bps
Net income	2,683	2,808	(4.5)	3,664	(26.8)

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions)

Exhibit 3: Standalone 1QFY27 – Revenue accelerated to 12% yoy; EBITDA up 2% yoy; EBITDAM compressed 236bps qoq to 25%

Standalone (Rs mn)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	yoy (%)	qoq (%)
Revenue	23,381	22,467	20,959	21,630	21,047	19,469	20,836	22,604	23,474	11.5	3.8
Growth yoy (%)	10	-0	-7	-7	-10	-13	-1	5	12		
Expenditure	16,866	16,212	14,861	15,464	15,329	13,958	15,172	16,431	17,617	14.9	7.2
as a % of sales	72.1	72.2	70.9	71.5	72.8	71.7	72.8	72.7	75.0		
Consumption of RM	9,777	9,167	8,401	8,576	8,156	7,053	8,086	9,162	9,188	12.6	0.3
as a % of sales	41.8	40.8	40.1	39.6	38.8	36.2	38.8	40.5	39.1		
Employee cost	1,626	1,617	1,583	1,539	1,696	1,674	1,708	1,683	1,859	9.6	10.5
as a % of sales	7.0	7.2	7.6	7.1	8.1	8.6	8.2	7.4	7.9		
Other expenditure	5,463	5,428	4,877	5,348	5,477	5,232	5,379	5,587	6,571	20.0	17.6
as a % of sales	23.4	24.2	23.3	24.7	26.0	26.9	25.8	24.7	28.0		
EBITDA	6,515	6,254	6,098	6,167	5,718	5,511	5,664	6,173	5,857	2.4	(5.1)
Growth yoy (%)	19	3	-8	-6	-12	-12	-7	0	2		
EBITDA margin (%)	27.9	27.8	29.1	28.5	27.2	28.3	27.2	27.3	25.0		
Depreciation	1,094	1,083	1,104	1,122	1,125	1,112	1,120	1,124	1,150	2.3	2.3
EBIT	5,420	5,171	4,995	5,045	4,593	4,399	4,544	5,049	4,707	2.5	(6.8)
Other income	446	348	314	481	422	465	273	285	343	(18.8)	20.3
Interest	702	635	573	588	522	483	414	402	432	(17.3)	7.4
PBT	5,164	4,884	4,735	4,937	4,493	4,380	4,402	4,932	4,618	2.8	(6.4)
Total tax	1,014	1,407	1,266	1,278	1,108	1,202	1,035	1,180	1,159	4.6	(1.8)
Adjusted PAT	4,151	3,476	3,470	3,659	3,385	3,178	3,367	3,752	3,459	2.2	(7.8)
Growth yoy (%)	33	-0	-8	-9	-18	-9	-3	3	2		
Extraordinary loss/(gain)	1,457	-135	9	203	0	79	487	4,930	245		
Reported PAT	2,694	3,612	3,460	3,456	3,385	3,099	2,880	-1,178	3,214	(5.1)	(372.9)
Adjusted EPS (Rs)	8.9	7.5	7.5	7.9	7.3	6.8	7.2	8.1	7.4	2.2	(7.8)

(%)	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27	yoy (bps)	qoq (bps)
EBITDAM	27.9	27.8	29.1	28.5	27.2	28.3	27.2	27.3	25.0	(222)	(236)
EBITM	23.2	23.0	23.8	23.3	21.8	22.6	21.8	22.3	20.1	(177)	(229)
EBTM	22.1	21.7	22.6	22.8	21.3	22.5	21.1	21.8	19.7	(168)	(215)
PATM	17.8	15.5	16.6	16.9	16.1	16.3	16.2	16.6	14.7	(135)	(186)
Effective tax rate	19.6	28.8	26.7	25.9	24.7	27.4	23.5	23.9	25.1	44	117

Source: Company, Emkay Research

Exhibit 4: BHFC's defense order book stands at ~Rs112bn, as of 1QFY27**Defence order book (Rs bn)**

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Exhibit 5: Per management commentary of major CV OEMs, outlook for EU/NA CVs is improving

Daimler Trucks	CY25 Actuals	CY26 Earlier Forecast	CY26 Revised Forecast	Revision in Guidance (%)	Date
North America HD trucks	258,000	250,000-290,000	250,000-290,000	Maintained guidance	Aug-26
Europe HD trucks	305,000	290,000-330,000	290,000-330,000	Maintained guidance	Aug-26

Volvo Trucks	CY25 Actuals	CY26 Earlier Forecast	CY26 Revised Forecast	Revision in Guidance (%)	Date
North America HD trucks	258,000	265,000	265,000	0	Jul-26
Europe HD trucks	296,000	305,000	315,000	3	Jul-26

Paccar (>16T market)	CY25 Actuals	CY26 Earlier Forecast	CY26 Revised Forecast	Revision in Guidance (%)	Date
US & Canada	235,000	230,000-270,000	230,000-270,000	0	Jul-26
Europe	290,000	280,000-320,000	290,000-330,000	3	Jul-26


Traton	CY25 Actuals	CY26 Earlier Forecast	CY26 Revised Forecast	Revision in Guidance (%)	Date
North America Class 6-8	363,000	NA	-5% to +10%	NA	Apr-26
North America Class 8	259,000	NA	-5% to +10%	NA	Apr-26
Europe (>6T)	336,000	NA	-2.5% to +7.5%	NA	Apr-26

Source: Company, Emkay Research

Exhibit 6: We build in 22%/25%/32% revenue/EBITDA/PAT CAGR over FY26-29E

Rs mn	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E	FY26-29E CAGR (%)
Segmental revenues									
India CV	7,417	10,140	10,341	9,626	10,365	11,194	12,314	13,545	9%
Growth (%)	45	37	2	(7)	8	8	10	10	
India Non-Auto (Bulk of this is Defence)	11,665	12,978	22,360	23,283	25,231	32,047	39,306	44,642	21%
Growth (%)	57	11	72	4	8	27	23	14	
-- of which Defence	4,078	4,103	15,606	17,000	15,620	21,500	27,650	31,760	
Growth (%)		1	280	9	(8)	38	29	15	
India PV	2,936	3,513	2,997	3,622	3,973	4,489	5,028	5,632	12%
Growth (%)	36	20	(15)	21	10	13	12	12	
Export CV	17,180	19,120	21,134	20,144	13,246	18,399	23,877	31,107	33%
Growth (%)	79	11	11	(5)	(34)	39	30	30	
Export Non-Auto	13,932	15,933	15,454	15,962	15,413	17,315	19,537	22,147	13%
Growth (%)	151	14	(3)	3	(3)	12	13	13	
Export PV	5,591	9,552	12,694	11,174	11,455	13,746	15,808	18,179	17%
Growth (%)	24	71	33	(12)	3	20	15	15	
Others	2,978	3,452	3,546	3,724	4,273	4,846	5,330	5,863	11%
Growth (%)	78	16	3	5	15	13	10	10	
Total standalone revenues	62,546	75,727	89,686	88,437	83,956	102,037	121,200	141,116	19%
Growth (%)	71.3	21.1	18.4	-1.4	-5.1	21.5	18.8	16.4	
Subsidiary revenues	42,065	53,375	67,134	62,791	84,160	104,511	125,843	152,031	
Growth (%)	57	27	26	(6)	34	24	20	21	
Consolidated revenues	104,611	129,103	156,821	151,228	168,117	206,548	247,043	293,147	20%
Growth (%)	65.1	23.4	21.5	-3.6	11.2	22.9	19.6	18.7	
EBITDA	19,810	17,675	25,579	26,939	29,267	38,621	47,676	57,453	25%
Growth (%)	129	(11)	45	5	9	32	23	21	
EBITDA margin %	18.9	13.7	16.3	17.8	17.4	18.7	19.3	19.6	
PAT	9,544	5,742	9,635	10,982	12,341	16,543	22,750	28,681	32%
PAT margin %	15.3	7.6	10.7	12.4	14.7	16.2	18.8	20.3	
EPS (Rs)	20.5	12.3	20.7	23.0	25.8	34.6	47.6	60.0	32%
ROCE (%)	12.5	9.2	13.7	13.5	13.6	17.1	19.6	21.6	
ROE (%)	15.9	8.6	13.9	13.4	13.1	16.3	19.6	21.1	
Net D/E (x)	0.5	0.7	0.7	0.4	0.5	0.4	0.3	0.2	
P/E (x)	102.1	169.7	101.2	91.1	81.1	60.5	44.0	34.9	

Source: Company, Emkay Research

Exhibit 7: BHFC currently trades close to 1SD above its LTA on 1YF EV/EBITDA basis

Source: Company, Bloomberg, Emkay Research

Exhibit 8: We raise FY27E/FY28E EPS by 4-5% on better-than-expected gross margin recovery

Consolidated (Rs mn)	FY26		FY27E				FY28E				FY29E	
	Actual	% yoy	Earlier	Revised	% Change	% yoy	Earlier	Revised	% Change	% yoy	Introduced	% yoy
Revenues	168,117	11.2	209,786	206,548	(1.5)	22.9	248,681	247,043	(0.7)	19.6	293,147	18.7
EBITDA	29,267	8.6	37,549	38,621	2.9	32.0	46,500	47,676	2.5	23.4	57,453	20.5
Margin (%)	17.4	-41 bps	17.9	18.7	80 bps	129 bps	18.7	19.3	60 bps	60 bps	19.6	30 bps
Net profit	12,341	12.4	15,793	16,543	4.8	34.1	21,933	22,750	3.7	37.5	28,681	26.1
EPS (Rs)	25.8	9.5	33.0	34.6	4.8	34.1	45.9	47.6	3.7	37.5	60.0	26.1

Source: Company, Bloomberg, Emkay Research

Exhibit 9: Emkay's Auto universe – Valuation metrics

Company name	Price (Rs)	Reco	Target price (Rs)	% Upside / (Downside)	FY26-28E Revenue CAGR	FY26-28E EPS CAGR	PER (x)			PBV (x)			EV/EBITDA (x)			ROE (%)		
							FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E	FY26	FY27E	FY28E
JK Tyre	385	Buy	600	55.8	12%	14%	12.0	15.7	9.2	1.8	1.7	1.5	7.7	8.9	6.4	16.7	11.2	17.0
Apollo Tyres	446	Buy	575	28.9	11%	-3%	11.8	16.1	12.4	1.7	1.6	1.4	7.5	7.5	6.0	15.3	10.1	11.9
CEAT	3,794	Buy	4,500	18.6	15%	19%	19.9	21.7	14.1	3.0	2.7	2.4	8.6	8.1	6.2	16.3	13.3	18.0
Pricol	733	Buy	800	9.1	18%	23%	35.6	30.6	23.7	7.1	5.9	4.9	18.6	15.6	12.4	22.1	21.1	22.6
Craftsman Automation	10,280	Buy	11,900	15.8	18%	45%	61.8	40.8	29.5	7.5	4.6	4.0	22.2	16.9	14.0	13.0	14.4	14.4
Bharat Forge	2,093	Buy	2,400	14.7	21%	45%	81.1	60.5	44.0	10.4	9.3	8.0	35.8	27.0	21.7	13.1	16.3	19.6
Minda Corporation	739	Buy	775	4.9	19%	25%	49.1	40.7	31.4	6.7	5.4	4.7	20.9	17.8	14.8	14.8	14.9	16.0
MSUMI	41	Buy	50	21.8	19%	33%	45.6	34.2	25.7	12.2	10.9	9.9	25.0	19.3	15.6	32.4	36.2	41.3
Sandhar Technologies	652	Buy	950	45.7	14%	35%	25.5	18.0	14.1	2.9	2.6	2.3	10.6	8.8	7.3	12.4	15.3	17.1
SAMIL	168	Buy	180	7.1	15%	38%	44.7	30.6	23.5	4.3	3.9	3.4	14.5	12.3	9.6	10.5	13.4	15.4
Shriram Pistons & Rings	4,434	Buy	4,850	9.4	27%	21%	33.5	27.2	23.1	6.7	5.5	4.5	22.9	17.0	14.1	22.0	22.2	21.4
Suprajit Engineering	529	Buy	625	18.2	14%	31%	38.1	26.0	22.1	5.0	4.4	3.8	19.7	13.5	11.7	14.0	18.1	18.6
SJS Enterprises	2,372	Buy	2,800	18.0	20%	27%	44.5	33.8	27.4	8.7	6.9	5.6	28.1	22.7	19.2	22.1	22.8	22.4
Uno Minda	1,288	Reduce	1,100	-14.6	20%	31%	60.7	54.8	42.8	10.4	8.9	7.6	32.4	22.8	22.4	19.5	18.1	20.4

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

Bharat Forge: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	151,228	168,117	206,548	247,043	293,147
Revenue growth (%)	(3.6)	11.2	22.9	19.6	18.7
EBITDA	26,939	29,267	38,621	47,676	57,453
EBITDA growth (%)	5.3	8.6	32.0	23.4	20.5
Depreciation & Amortization	8,736	9,709	11,337	12,086	12,926
EBIT	18,203	19,557	27,284	35,590	44,526
EBIT growth (%)	6.5	7.4	39.5	30.4	25.1
Other operating income	-	-	-	-	-
Other income	2,138	1,987	2,086	2,170	2,256
Financial expense	4,175	3,233	3,623	3,517	3,689
PBT	16,166	18,311	25,747	34,242	43,094
Extraordinary items	(1,571)	(1,544)	0	0	0
Taxes	5,426	5,778	9,011	11,300	14,221
Minority interest	-	-	-	-	-
Income from JV/Associates	242	(192)	(192)	(192)	(192)
Reported PAT	9,412	10,797	16,543	22,750	28,681
PAT growth (%)	(1.0)	14.7	53.2	37.5	26.1
Adjusted PAT	10,982	12,341	16,543	22,750	28,681
Diluted EPS (Rs)	23.0	25.8	34.6	47.6	60.0
Diluted EPS growth (%)	11.0	12.4	34.1	37.5	26.1
DPS (Rs)	8.8	8.3	8.6	10.6	11.6
Dividend payout (%)	44.8	36.7	24.8	22.2	19.4
EBITDA margin (%)	17.8	17.4	18.7	19.3	19.6
EBIT margin (%)	12.0	11.6	13.2	14.4	15.2
Effective tax rate (%)	33.6	31.6	35.0	33.0	33.0
NOPLAT (pre-IndAS)	12,094	13,386	17,735	23,845	29,833
Shares outstanding (mn)	478	478	478	478	478

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
PBT (ex-other income)	14,521	16,766	25,747	34,242	43,094
Others (non-cash items)	730	0	0	0	0
Taxes paid	(6,050)	(5,606)	(8,770)	(10,979)	(13,817)
Change in NWC	(3,457)	(2,885)	(6,762)	(9,656)	(17,142)
Operating cash flow	17,963	21,218	25,175	29,211	28,750
Capital expenditure	(14,439)	(19,982)	(10,000)	(12,000)	(12,000)
Acquisition of business	-	-	-	-	-
Interest & dividend income	-	-	-	-	-
Investing cash flow	(19,643)	(16,740)	(12,000)	(15,000)	(15,000)
Equity raised/(repaid)	16,500	0	0	0	0
Debt raised/(repaid)	(12,944)	5,862	7,441	3,943	3,676
Payment of lease liabilities	0	0	0	0	0
Interest paid	(4,729)	(3,233)	(3,623)	(3,517)	(3,689)
Dividend paid (incl tax)	(4,221)	(3,958)	(4,105)	(5,054)	(5,560)
Others	3,089	0	0	0	0
Financing cash flow	(2,306)	(1,330)	(287)	(4,628)	(5,573)
Net chg in Cash	(3,985)	3,149	12,888	9,583	8,177
OCF	17,963	21,218	25,175	29,211	28,750
Adj. OCF (w/o NWC chg.)	21,421	24,103	31,938	38,867	45,892
FCFF	3,524	1,236	15,175	17,211	16,750
FCFE	(651)	(1,997)	11,552	13,694	13,061
OCF/EBITDA (%)	66.7	72.5	65.2	61.3	50.0
FCFE/PAT (%)	(6.9)	(18.5)	69.8	60.2	45.5
FCFF/NOPLAT (%)	29.1	9.2	85.6	72.2	56.1

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	956	956	956	956	956
Reserves & Surplus	91,577	94,842	106,331	123,522	146,087
Net worth	92,533	95,798	107,288	124,478	147,044
Minority interests	(328)	(230)	(38)	154	346
Non-current liab. & prov.	(703)	(1,907)	(1,665)	(1,344)	(940)
Total debt	62,884	68,746	76,187	80,131	83,806
Total liabilities & equity	154,387	162,408	181,772	203,418	230,255
Net tangible fixed assets	28,723	28,588	29,308	28,513	27,476
Net intangible assets	103	103	103	103	103
Net ROU assets	-	-	-	-	-
Capital WIP	17,317	12,984	6,498	7,797	7,797
Goodwill	2,628	3,903	3,903	3,903	3,903
Investments [JV/Associates]	7,379	5,927	7,927	8,927	9,927
Cash & equivalents	26,443	21,639	34,527	46,110	56,287
Current assets (ex-cash)	81,855	98,059	114,673	137,156	165,162
Current Liab. & Prov.	44,595	58,069	68,871	82,203	93,623
NWC (ex-cash)	37,259	39,990	45,802	54,953	71,539
Total assets	154,387	162,408	181,772	203,418	230,255
Net debt	36,441	47,108	41,660	34,021	27,519
Capital employed	154,387	162,408	181,772	203,418	230,255
Invested capital	103,247	121,858	132,819	140,584	156,244
BVPS (Rs)	193.5	200.4	224.4	260.3	307.5
Net Debt/Equity (x)	0.4	0.5	0.4	0.3	0.2
Net Debt/EBITDA (x)	1.4	1.6	1.1	0.7	0.5
Interest coverage (x)	4.9	6.7	8.1	10.7	12.7
RoCE (%)	13.5	13.5	16.9	19.5	21.5

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	106.3	92.7	60.5	44.0	34.9
P/CE(x)	50.8	45.4	35.9	28.7	24.1
P/B (x)	10.8	10.4	9.3	8.0	6.8
EV/Sales (x)	6.9	6.2	5.0	4.2	3.5
EV/EBITDA (x)	38.5	35.8	27.0	21.7	17.9
EV/EBIT(x)	57.0	53.6	38.2	29.1	23.1
EV/IC (x)	10.0	8.6	7.8	7.4	6.6
FCFF yield (%)	0.3	0.1	1.5	1.7	1.6
FCFE yield (%)	(0.1)	(0.2)	1.2	1.4	1.3
Dividend yield (%)	0.4	0.4	0.4	0.5	0.6
DuPont-RoE split					
Net profit margin (%)	7.3	7.3	8.0	9.2	9.8
Total asset turnover (x)	1.0	1.1	1.2	1.3	1.4
Assets/Equity (x)	1.8	1.7	1.7	1.7	1.6
RoE (%)	13.4	13.1	16.3	19.6	21.1
DuPont-RoIC					
NOPLAT margin (%)	8.0	8.0	8.6	9.7	10.2
IC turnover (x)	1.5	1.5	1.6	1.8	2.0
RoIC (%)	11.8	11.9	13.9	17.4	20.1
Operating metrics					
Core NWC days	89.9	86.8	80.9	81.2	89.1
Total NWC days	89.9	86.8	80.9	81.2	89.1
Fixed asset turnover	1.3	1.2	1.3	1.4	1.6
Opex-to-revenue (%)	38.6	37.4	36.6	36.3	36.0


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
07-May-26	1,993	2,100	Buy	Chirag Jain
09-Mar-26	1,862	2,100	Buy	Chirag Jain
13-Feb-26	1,739	2,000	Buy	Chirag Jain
12-Nov-25	1,389	1,450	Add	Chirag Jain
07-Aug-25	1,162	1,200	Add	Chirag Jain
09-May-25	1,166	1,200	Add	Chirag Jain
16-Apr-25	1,055	1,200	Add	Chirag Jain
13-Feb-25	1,076	1,300	Buy	Chirag Jain
10-Jan-25	1,210	1,550	Buy	Chirag Jain
18-Nov-24	1,305	1,700	Buy	Chirag Jain

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 10, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 10, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 10, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)